KentCShihMD

PubMed

• 22 citations
  Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up
  Sandra P. D'Angelo, Shailender Bhatia, A.S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Céleste Lebbé, Karl D. Lewis, Gerald...> ;ESMO Open. 2021 Oct 26
• 113 citations
  Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
  Sandra P. D'Angelo, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Céleste Lebbé, Karl D. Lewis, G...> ;Journal for Immunotherapy of Cancer. 2020 May 1
• 24 citations
  A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squam...
  David R. Spigel, Dianna Shipley, David M. Waterhouse, Suzanne F. Jones, Patrick J. Ward, Kent C. Shih, Brian Hemphill, Michael McCleod, Robert C. Whorf, Ray D. Page, J...> ;The Oncologist. 2019 Dec 1
• 26 citations
  Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
  John D. Hainsworth, Kevin P. Becker, Tarek Mekhail, Sajeel A. Chowdhary, Janice Faulkner Eakle, David Wright, Robert M. Langdon, Kathleen Yost, Gilbert Darin Anthony P...> ;Journal of Neuro-Oncology. 2019 Aug 7
• 5 citations
  Regorafenib Prior to Selective Internal Radiation Therapy Using 90Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety...
  Andrew S. Kennedy, Dianna Shipley, Max Shpak, Laura Blakely, Brian Hemphill, Kent C. Shih, Cassie M. Lane, Lisa Zimmerman, Andrew J. McKenzie, Mark Mainwaring, James D...> ;Frontiers in Oncology. 2019 Jul 10
• 19 citations
  Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
  Sandra P. D'Angelo, Matthias Hunger, Andrew S. Brohl, Paul Nghiem, Shailender Bhatia, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, C...> ;Cancer Immunology, Immunotherapy. 2019 Feb 5
• 70 citations
  A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies
  Drew W. Rasco, Kyriakos P. Papadopoulos, Michael Pourdehnad, Anita Gandhi, Patrick Hagner, Yan Li, Xin Wei, Rajesh Chopra, Kristen Hege, Jorge DiMartino, Kent C. Shih> ;Clinical Cancer Research. 2019 Jan 1
• 98 citations
  Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
  Rimas V. Lukas, Jordi Rodon, Kevin P. Becker, Eric T. Wong, Kent C. Shih, Mehdi Touat, Marcella Fassò, S. Osborne, Luciana Molinero, Carol O'Hear, William Grossman, Jo...> ;Journal of Neuro-Oncology. 2018 Aug 2
• 199 citations
  Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN ...
  Johann S. de Bono, Ugo De Giorgi, Daniel Nava Rodrigues, Christophe Massard, Sergio Bracarda, Albert Font, Jose Angel Arranz Arija, Kent C. Shih, George Daniel Radavoi...> ;Clinical Cancer Research. 2019 Feb 1
• 11 citations
  Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo-controlled phase 2 trial with...
  David R. Spigel, Howard A. Burris, F. Anthony Greco, Kent C. Shih, Victor G. Gian, Andrew Lipman, Davey B. Daniel, David M. Waterhouse, L Finney, John V. Heymach, John...> ;Cancer. 2018 Jun 1
• 8 citations
  Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
  John D. Hainsworth, David M. Waterhouse, Kent C. Shih, Ralph V. Boccia, Victor M. Priego, Michael McCleod, Fred J. Kudrik, Reed Brian Mitchell, Howard A. Burris, F. An...> ;Lung Cancer. 2018 Apr 1
• 218 citations
  Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical tr...
  Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D'Angelo, Kent C. Shih, Céleste Lebbé, Michele Milella, Isaac Browne...> ;Journal for Immunotherapy of Cancer. 2018 Jan 19
• 9 citations
  Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the ...
  David R. Spigel, Mark S. Rubin, Victor G. Gian, Dianna Shipley, Howard A. Burris, Rebecca A. Kosloff, Kent C. Shih, Raven Quinn, F. Anthony Greco, John D. Hainsworth> ;Lung Cancer. 2017 Nov 1
• 856 citations
  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
  , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2016 Oct 1
• 85 citations
  A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
  Kent C. Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B. Weir, Gregg C. Shepard, Jeffrey T. Williams, Mythili Shastry, Howard A. Burris, John D. Hainsworth> ;Journal of Neuro-Oncology. 2016 Jun 16
• 14 citations
  A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers
  Johanna C. Bendell, Ahmed Zakari, Evan Z. Lang, David M. Waterhouse, Douglas Flora, Kathryn B. Alguire, Michael McCleod, N. W. Peacock, Peter Ruehlman, Cassie M. Lane,...> ;Cancer Investigation. 2016 Apr 29
• 62 citations
  A phase I dose‐escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC‐223 in patient...
  Johanna C. Bendell, Robin Kate Kelley, Kent C. Shih, Jennifer A. Grabowsky, Emily K. Bergsland, Suzanne F. Jones, Thomas Martin, Jeffrey R. Infante, Paul S. Mischel, T...> ;Cancer. 2015 Oct 1
• 70 citations
  A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
  Johanna C. Bendell, Carla Kurkjian, Jeffrey R. Infante, Todd M. Bauer, Howard A. Burris, F. Anthony Greco, Kent C. Shih, D. S. Thompson, Cassie M. Lane, L Finney, Suza...> ;Investigational New Drugs. 2015 Feb 25
• 78 citations
  Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
  Kent C. Shih, Hendrik Tobias Arkenau, Jeffrey R. Infante> ;Drugs. 2014 Oct 25
• 20 citations
  Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma
  Kent C. Shih, Mythili Shastry, Jeffrey T. Williams, Peter F. Jelsma, Steven R Abram, Kanyalakshmi Ayyanar, Howard A. Burris, Jeffrey R. Infante> ;Journal of Clinical Oncology. 2014 Oct 10
• 13 citations
  Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Resear...
  Ralph J. Hauke, Jeffrey R. Infante, Mark S. Rubin, Kent C. Shih, Edward Arrowsmith, John D. Hainsworth> ;Melanoma Research. 2013 Dec 1
• 64 citations
  Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
  John D. Hainsworth, Kent C. Shih, Gregg C. Shepard, Guy W Tillinghast, Brett T Brinker, David R. Spigel> ;Clinical Advances in Hematology & Oncology. 2012 Apr 1
• Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial.
  Barton JH, Shih KC, Raefsky E, Haines DW, Strike B, Hainsworth JD, Burris HA, Yardley DA> ;J. Clin. Oncol.. 2011-05-20
• A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 2...
  Shih KC, Infante JR, Papadopoulos KP, Bendell JC, Tolcher AW, Burris HA, Beeram M, Jackson L, Arcos R, Westin EH, Farrington D, McGlothlin A, Hynes S, Leohr J, Brandt ...> ;J. Clin. Oncol.. 2011-05-20
• Join now to see all

Journal Articles

• Randomized Phase II Study of Akt Blockade with or Without Ipatasertib in Abiraterone-Treated Patients with Metastatic Prostate Cancer with and Without PTEN Loss  
  Kent Shih, MD, Clinical Cancer Research
• A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies  
  Kent C Shih, Kyriakos P Papadopoulos, Drew W Rasco, Clinical Cancer Research

Lectures

• Dianhydrogalactitol in bevacizumab-refractory GBM: Further analysis of a phase 1-2 trial. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018